Robust performance in challenging markets; volumes stabilising
ZURICH, Nov. 5, 2024 /PRNewswire/ --
Revenues -5% yoy organic TDA, -3% yoy organic, a solid result given market conditions, high comparison base; volumes stabilising
By GBU, Adecco -5%, with good results across Asia, Iberia, EEMENA, LatAm outweighed by challenging markets, particularly in France, US; Akkodis -5%, with Consulting +2%; LHH -7%, with Recruitment Solutions stable qoq
Resilient 19.4% gross margin, sequentially flat, reflecting lower volumes, current business mix, firm pricing
SG&A expenses improved to ?925 million, -5% yoy, with G&A -10% yoy and at 3.2% of revenues
Robust 3.3% EBITA margin, reflecting strong G&A savings, selective protection of sales and delivery capacity
Operating income ?162 million; Net income ?99 million; Basic EPS ?0.59; Adjusted EPS ?0.68
Operating cash flow +?121 million, weighed by timing differences; Free cash flow +?117 million YTD, higher yoy
Continued delivery of Simplify-Execute-Grow agenda:
G&A savings run-rate end-24 lifted to ?171 million
Reprioritised IT/digital plan: accelerating AI adoption, expanding Global Delivery to improve fill rates, time-to-fill
Strong track record of market share gains; relative revenue growth, reported, +850 bps since introduction of Simplify-Execute-Grow (Q3 22), and +290 bps YTD
Denis Machuel, Adecco Group CEO, commented:
"We continue to successfully deliver on our Simplify, Execute, Grow plan and third quarter performance was robust, against a high comparison base. The macroeconomic environment remains challenging, but I am encouraged to see that volume trends have stabilised.
We made further G&A savings in the quarter, allowing us to lift the year-end run-rate. We have reprioritised our IT/digital plans to accelerate AI adoption, and to expand Global Delivery to our top 25 customers. This will boost recruiter productivity and improve fill rates and time-to-fill, supporting profitable growth. We remain focused on capturing market share, building on strong progress over the last two years, and have positioned resources to capture growth opportunities as the market recovers."
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., presented data at the American Epilepsy Society (AES) Annual Meeting, showcasing its antiseizure...
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...